Screener Summaries Updates Institutions Sign In More Updates › Leadership & Pay › FBLG Leadership & Pay · Aug 24, 2026
FibroBiologics, Inc. appointed Leigh Steinberg as a Class II director of its Board of Directors, effective August 20… FBLG FibroBiologics, Inc.
FibroBiologics, Inc. appointed Leigh Steinberg as a Class II director of its Board of Directors, effective August 20, 2026, with his term expiring at the 2028 annual meeting. Mr. Steinberg will receive compensation consistent with other non-employee directors and signed a standard indemnification agreement. The company operates in the biotechnology industry, developing therapeutics for chronic diseases using fibroblasts.
More from FibroBiologics, Inc. FibroBiologics raises $1.02M via convertible debenture and issues commitment shares to Peak One Oct 8, 2026 FibroBiologics raises $0.5M in private placement from CSO Hamid Khoja at $1.675 per unit Sep 18, 2026 FibroBiologics raises $0.5 million via private placement of common stock and warrants Sep 15, 2026 Matt Link resigned from the Board of Directors of FibroBiologics, Inc. effective July 2, 2026 Jul 9, 2026 FibroBiologics, Inc. entered into a Securities Purchase Agreement on June 25, 2026, for a private placement offering… Jun 29, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
